K.V. Menshikov1,2, A.V. Sultanbaev1,2, Sh.I. Musin1, R.B. Valiakhmedov1, V.S. Chalov3, M.M. Zamilov1, I.A. Menshikova2, N.I. Sultanbaeva1, I.I. Abdullin1, R.F. Zakirova1
1Republican Clinical Oncology Dispensary, Ufa
2Bashkir State Medical University, Ufa
3LLC «PET-Technology Center» OP «Center for Nuclear Medicine in Ufa», Ufa
Menshikov Konstantin V. ― Cand. of Sci. (Med.), Associate Professor of the Department of Oncology and Clinical Morphology of the Bashkir State Medical University; oncologist of the Department of Chemotherapy of the Republican Clinical Oncology Dispensary
73/1 Oktyabrya Ave., Ufa, 450054, Russian Federation, e-mail: kmenshikov80@bk.ru, ORCID ID: 0000-0003-3734-2779
Abstract. Skin melanoma in the Russian Federation accounted for 1.82% of all malignant neoplasms of the adult population in 2018 and 12.65% of all skin tumors, but it accounts for 70.3% of deaths from all skin cancers. In the Republic of Bashkortostan in 2022, only 161 patients with skin melanoma were identified, of which 8.7% had metastatic disease. Until 2011, chemotherapy was the mainstay of treatment for metastatic melanoma; however, this approach provides only a 6-month median overall survival and 25% one-year overall survival. Ipilimumab, nivolumab, and pembrolizumab were the first drugs to demonstrate improved overall survival in patients with metastatic melanoma. Currently, another PD‑1 inhibitor, prolgolimab, is registered in the Russian Federation for the treatment of metastatic and unresectable melanoma. The presented clinical observation demonstrates the capabilities of prolgolimab. The patient received 59 courses of prolgolimab therapy with a complete response recorded.
Key words: melanoma, checkpoint inhibitors, prolgolimab, nivolumab, pembrolizumab, ipilimumab, overall survival, objective response rate.